Advertisement

Topics

Fibrotic Diseases Treatment Well Tolerated in Phase 1 Trial

10:42 EDT 22 Aug 2017 | PharmPro

PharmAkea announces successful completion of a Phase 1 trial in healthy subjects for its novel LOXL2 inhibitor, PAT-1251.
Contributed Author: 
PharmAkea

Original Article: Fibrotic Diseases Treatment Well Tolerated in Phase 1 Trial

NEXT ARTICLE

More From BioPortfolio on "Fibrotic Diseases Treatment Well Tolerated in Phase 1 Trial"

Advertisement
Quick Search
Advertisement
Advertisement